This international study examined the role of bone marrow morphology in distinguishing essential thrombocythemia (ET) from early/prefibrotic primary myelofibrosis (PMF) that clinically presents like ET. Bone marrow specimens of 1104 ET, obtained within one year of diagnosis, underwent a central re-review. Diagnosis was confirmed as ET in 891 patients (81%) and revised to early/prefibrotic PMF in 180 (16%); 33 cases were not evaluable. Ten/15-year survival (76%/59% vs. 89%/80%), leukemic transformation (5.8%/11.7% vs. 0.7%/2.1%) and fibrotic progression (12.3%/16.9% vs. 0.8%/9.3%) rates were significantly worse in early/prefibrotic PMF vs. ET; the respective death, leukemia and myelofibrosis incidence rates per 100 patient-years were 2.7% vs.
